BioTime Inc. is a clinical-stage biotechnology company, headquartered in the San Francisco Bay Area, focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery matrix technology.
GoLiver Therapeutics is a biotechnology company based in France that spun out of the medical research institute INSERM and the Université de Nantes. The company has a focus on regenerative medicine for patients in need of a transplantation. All surgery carries risk and compatible donors are not always available. GoLiver intends to use pluripotent stem cells to regenerate damaged livers, avoiding a transplantation. The company is developing an injectable allogeneic hepatocyte cell therapy to be derived from an unlimited supply of human pluripotent stem cells.
Biotime has licensed one of its pluripotent cell lines to Goliver Therapeutics. The BioTime cell lines are thoroughly characterized and NIH-registered. They also include all necessary donor history and full documentation. According to Biotime using an NIH-registered cell line helps address key FDA concerns related to cell therapies at the onset, which could have a positive impact on development timelines and the regulatory process.
“We are excited to help enable the team at Goliver to further their mission to treat liver diseases with differentiated cells created from one of our cell lines,” … “The potential applications of our pluripotent cell technology are immense. Various cell lines of ours are being used by researchers around the world. We are happy to enable companies, like Goliver, which are advancing therapeutic candidates in areas that are not a core focus of BioTime’s own development efforts.” – Adi Mohanty, Co-CEO of BioTime.
Source:
